A Randomized, Double-Blind, Placebo-Controlled Multicenter Study of Levosimendan Therapy in low ejection fraction Takotsubo Syndrome (LevoTako Trial)

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-515060-32-00

Acronym

NBK182/1/2022

Enrollment

190

Registered

2024-12-16

Start date

2024-11-22

Completion date

2025-12-22

Last updated

2025-12-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Takotsubo syndrome

Brief summary

In-hospital LVEF recovery

Detailed description

Composite endpoint including 12-month all-cause mortality or major adverse cardiovascular events rate (rehospitalization due to TTS recurrence or heart failure, stroke or TIA, whatever occurs first)

Interventions

DRUGSimdax

DRUG2

DRUG5 mg/mL

DRUGkoncentrat do sporządzania roztworu do infuzji

DRUGGLUCOSUM 5% FRESENIUS

DRUG50 mg/ml

DRUGroztwór do infuzji

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
In-hospital LVEF recovery	—

Secondary

Measure	Time frame
Composite endpoint including 12-month all-cause mortality or major adverse cardiovascular events rate (rehospitalization due to TTS recurrence or heart failure, stroke or TIA, whatever occurs first)	—

Countries

Poland

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026